International deal for Phylogica
SUBIACO-BASED drug discovery firm Phylogica has announced an agreement with Europe’s largest pharmaceutical company, Roche, to evaluate the firm’s disease-attacking technology.
Phylogica has the intellectual property rights to a unique collection of proteins called phylomers, which are focused on developing therapies for the treatment of inflammatory diseases such as asthma, acute stroke damage, and diabetes.
To read more, please login or register
I'd like to register please
8 free articles per month + business email alerts twice daily
Problems, questions, feedback? Please call
us on +61 8 9288 2100 during WST office hours
us on +61 8 9288 2100 during WST office hours
Category:
Comments:
BETA
Phylogica (PYC)
Total Shareholder Return as at 30/06/2012
| 1 year TSR | 5 year TSR | ||
|---|---|---|---|
| 114th | Ozgrowth | 6% | 0% |
| 118th | Questus | 131% | -50% |
| 328th | Phylogica | -39% | -34% |
| 494th | Resonance Health | -60% | -20% |
| 633rd | PharmAust | -79% | -38% |
680 WA listed companies ranked by 1 year TSR relative to WA companies with similar revenue
Shareholding
| Paul Watt | 16,253,700 | ||
| Nicholas Woolf | 8,471,960 | ||
| Bruce McHarrie | 2,304,580 | ||
| Graeme Boden | 422,917 | ||
| Doug Wilson | 250,000 |
Number of shares
Share Transactions
Total value as at the date of the transaction
Revenue
| 103rd |  | Ozgrowth | $2.7m |
| 104th |  | Questus | $2.6m |
| 105th | | Phylogica | $2.1m |
| 106th |  | Resonance Health | $1.8m |
| 107th | | PharmAust | $1.6m |
166 WA listed industrial companies ranked by revenue
Remuneration from Phylogica
| 388th | Paul Watt | $408k |
| 713th | Nicholas Woolf | $277k |
| 1214th | Doug Wilson | $120k |
Ranked by total remuneration from all listed WA companies
Rock art should be protected: Greens
19 Jun 2013
WA leads job ad drop
19 Jun 2013Satterley picks up 44-hectares in Wandi
18 Jun 2013Elders shares drop after rural sale...
18 Jun 2013
Buswell versus Carles takes a twist
18 Jun 2013
